(3,5-diaminophenyl)boronic acid | 89641-16-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (3,5-diaminophenyl)boronic acid
• 英文别名: 3,5-Diaminophenylboronic acid
• CAS: 89641-16-7
• 化学式: C₆H₉BN₂O₂
• mdl: MFCD11519193
• 分子量: 151.961
• InChiKey: VUQKYHBFROJAFA-UHFFFAOYSA-N

物化性质

• 沸点：
  491.0±55.0 °C(Predicted)
• 密度：
  1.33±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.07
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  92.5
• 氢给体数：
  4
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (3,5-diaminophenyl)boronic acid 在 三乙胺 作用下， 以 四氢呋喃 、 氯仿 为溶剂， 反应 26.0h， 生成 N-[3-[bis(methylsulfonyl)amino]-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-N-methylsulfonylmethanesulfonamide
  参考文献：
  名称：

  [EN] COMPOSITIONS FOR THE TREATMENT OF PULMONARY FIBROSIS
  [FR] COMPOSITIONS POUR LE TRAITEMENT D'UNE FIBROSE PULMONAIRE

  摘要：

  本发明涉及化合物及其在预防及/或治疗肺纤维化及/或相关病症的应用。

  公开号：

  WO2018018091A1
• 作为产物：
  描述：

  (3-amino-5-nitro)phenyl boronic acid 在 乙醇 、 镍 作用下， 生成 (3,5-diaminophenyl)boronic acid
  参考文献：
  名称：

  Torssell et al., Arkiv foer Kemi, 1957, vol. 10, p. 479,504

  摘要：

  DOI：

文献信息

• Tuning catalysis of boronic acids in microgels by <i>in situ</i> reversible structural variations
  作者：Zhenghao Zhai、Xue Du、Qingshi Wu、Lin Zhu、Zahoor H. Farooqi、Jin Li、Ruyue Lan、Yusong Wang、Weitai Wu

  DOI：10.1039/c9ra10541g

  日期：——

  their catalytic activity comparable or even superior to that of the corresponding free boronic acid monomers homogeneously dispersed in solutions and, more importantly, making these boronic-acid-containing polymer microgels able to catalyze alternate reactions that may extend the usefulness. This enhanced catalytic function of these boronic-acid-containing microgels as organoboron acid catalysts is plausibly

  固定在聚合物微凝胶中的硼酸的催化作用可以通过用 N 2 /CO 2气体鼓泡来调节，在某些情况下还可以通过添加葡萄糖来调节，使其催化活性与均匀分散的相应游离硼酸单体的催化活性相当甚至更好。解决方案，更重要的是，使这些含硼酸的聚合物微凝胶能够催化可能扩展用途的替代反应。这些含硼酸的微凝胶作为有机硼酸催化剂的这种增强的催化功能似乎是通过原位实现的可逆的结构变化。为了更好地理解催化过程，已经对模型硼酸催化的aza-Michael加成、醛醇、酰胺化和[4 + 2]环加成反应进行了动力学研究。
• Integrated Strategies for Identifying Leads That Target the NS3 Helicase of the Hepatitis C Virus
  作者：Steven R. LaPlante、Anil K. Padyana、Asitha Abeywardane、Pierre Bonneau、Mireille Cartier、René Coulombe、Araz Jakalian、Jessi Wildeson-Jones、Xiang Li、Shuang Liang、Ginette McKercher、Peter White、Qiang Zhang、Steven J. Taylor

  DOI：10.1021/jm401432c

  日期：2014.3.13

  Future treatments for individuals infected by the hepatitis C virus (HCV) will likely involve combinations of compounds that inhibit multiple viral targets. The helicase of HCV is an attractive target with no known drug candidates in clinical trials. Herein we describe an integrated strategy for identifying fragment inhibitors using structural and biophysical techniques. Based on an X-ray structure of apo HCV helicase and in silico and bioinformatic analyses of HCV variants, we identified that one site in particular (labeled 3 + 4) was the most conserved and attractive pocket to target for a drug discovery campaign. Compounds from multiple sources were screened to identify inhibitors or binders to this site, and enzymatic and biophysical assays (NMR and SPR) were used to triage the most promising ligands for 3D structure determination by X-ray crystallography. Medicinal chemistry and biophysical evaluations focused on exploring the most promising lead series. The strategies employed here can have general utility in drug discovery.
• [EN] COMPOSITIONS FOR THE TREATMENT OF PULMONARY FIBROSIS<br/>[FR] COMPOSITIONS POUR LE TRAITEMENT D'UNE FIBROSE PULMONAIRE
  申请人：VECTUS BIOSYSTEMS LTD

  公开号：WO2018018091A1

  公开（公告）日：2018-02-01

  The present invention relates to compounds and their use in the prophylactic and/or therapeutic treatment of pulmonary fibrosis and/or related conditions.

  本发明涉及化合物及其在预防及/或治疗肺纤维化及/或相关病症的应用。
• Torssell et al., Arkiv foer Kemi, 1957, vol. 10, p. 479,504
  作者：Torssell et al.

  DOI：——

  日期：——